RemeGen

RemeGen is one of the...

• CSI 500.

RemeGen is a company listed under the stock ticker 688331 (CN).

View the org chart displaying its 11 main executives

Most searched biographies at RemeGen

• Jianmin Fang, Chief Executive Officer and Chief Scientific Officer
• Yunjin Chen, Independent Non-Executive Director
• Weidong Wang, Chairman of the Board

Popular executive movements at RemeGen

• Shaojing Tong has joined the company as Chief Financial Officer and Joint Company Secretary of the Company  (posted on September 29 2023).
• Jian Lin, Executive Director, has left the company  (posted on September 5 2023).

Create your alert
to follow the executive moves at RemeGen.

RemeGen has 2,284 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Adaptive Phage Therapeutics (United States (USA)).

Popular M&A news in Biotechnology

• Karius has just announced a $100 Million fundraising (posted on May 3 2024).
• Transcarent has just announced a $126 Million fundraising (posted on May 2 2024).
• WindRose Health Investors has announced the acquisition of SubjectWell  (posted on May 2 2024).

Popular contacts in Biotechnology

• Ali Behbahani - Non-Executive Director at Adaptimmune Therapeutics
• Vik Bajaj - Director at Interline Therapeutics
• Khalil Barrage - Interim Chairman of the Board at Sensorion

Learn more about the Biotechnology industry >

Press releases by RemeGen

Social media about RemeGen

• RemeGen on Wikipedia, Google News & Yahoo Finance
• RemeGen on LinkedIn, Twitter & YouTube

Contact by email its executives including Jianmin Fang

Call RemeGen at +86 535...

View the org chart

Register to receive your alert

Report an error